NasdaqGS:PRLDBiotechs
Prelude Therapeutics (PRLD): Evaluating Valuation After Incyte Deal and Strategic Pipeline Shift
Prelude Therapeutics (PRLD) is shaking up its strategy with news of a major exclusive option agreement with Incyte and a renewed focus on its KAT6A breast cancer program. The company is also pausing the SMARCA2 clinical effort.
See our latest analysis for Prelude Therapeutics.
Prelude’s string of announcements, including the Incyte partnership, SMARCA2 pause, and executive change, has made for a volatile stretch, with the stock tumbling 25% over the last week alone. Share price momentum...